FTY720 induces apoptosis of human hepatoma cell lines through cell lines through P13-K-mediated Akt dephosphorylation

Carcinogenesis

Volumn 25, Issue 12, 2004, Pages 2397-2405

  Lee, Terence K ^a   Man, Kwan ^a,b   Ho, Joanna W ^a   Sun, Chris K ^a   Ng, Kevin T ^a   Wang, Xiang Hong ^a   Wong, Yong Chuan ^a   Ng, Irene O ^a   Xu, Ray ^a   Fan, Sheung Tat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CYCLIN D1; FINGOLIMOD; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P27; PROTEIN P42; PROTEIN P44; PROTEIN P53; SERINE; TRANSCRIPTION FACTOR FKHR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL IMMORTALIZATION; CELL STRAIN HEPG2; CELL SURVIVAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG SELECTIVITY; ENZYME INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER CELL CULTURE; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; RAT; STRAIN DIFFERENCE; UPREGULATION;

EID: 10344231428     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh250     Document Type: Article

References (33)

1. Ching,Y.P., Wong,C.M., Chan,S.F., Leung,T.H., Ng,D.C., Jin,D.Y. and Ng,I.O. (2003) Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J. Biol. Chem., 278, 10824-10830.
2. Azuma,H., Takahara,S., Ichimaru,N. et al. (2002) Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res., 62 1410-1419.
3. Azuma,H., Takahara,S., Horie,S., Muto,S., Otsuki,Y. and Katsuoka,Y. (2003) Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J. Urol. 169, 2372-2377.
4. Matsuoka,Y., Nagahara,Y., Ikekita,M. and Shinomiya,T. (2003) A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol., 138, 1303-1312.
5. Toker,A. (2000) Protein kinases as mediators of phosphoinositide 3-kinase signaling. Mol. Pharmacol., 57, 652-658.
6. Wen,J., Ramadevi,N., Nguyen,D., Perkins,C., Worthington,E. and Bhalla,K. (2000) Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood, 96, 3900-3906.
7. Yao,Y.J., Ping,X.L., Zhang,H. et al. (1999) PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene, 18, 3181-3185.
8. Simpson,L. and Parsons,R. (2001) PTEN: life as a tumor suppressor. Exp. Cell Res., 264, 29-41.
9. Azuma,H., Horie,S., Muto,S. et al. (2003) Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity. Anticancer Res., 23, 3183-3193.
10. Kimura,T., Hasegawa,T., Nakai,H., Azuma,T., Usui,N., Sasaki,T. and Okada,A. (2003) FTY720 reduces T-cell recruitment into marine intestinal allograft and prevents activation of graft-infiltrating cells. Transplantation, 75, 1469-1474.
11. Permpongkosol,S., Wang,J.D., Takahara,S., Matsumiya,K., Nonomura,N., Nishimura,K., Tsujimura,A., Kongkanand,A. and Okuyama,A. (2002) Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int. J. Cancer, 98, 167-172.
12. Suzuki,S., Enosawa,S., Kakefuda,T., Shinomiya,T., Amari,M., Naoe,S., Hoshino,Y. and Chiba,K. (1996) A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation, 61, 200-205.
13. Suzuki,S., Li,X.K., Enosawa,S. and Shinomiya,T. (1996) A new immunosuppressant, FTY720, induces bcl-2-associated apoptosic cell death in human lymphocytes. Immunology, 89, 518-523.
14. Nagahara,Y., Matsuoka,Y., Saito,K., Ikekita,M. and Higuchi,S. (2001) Coordinate involvement of cell cycle arrest and apoptosis strengthen the effect of FTY720. Jpn. J. Cancer Res., 92, 680-687.
15. Nakabayashi,H., Taketa,K., Miyano,K., Yamane,T. and Sato,J. (1982) Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res., 42, 3858-3863.
16. Brown,J.J., Parashar,B., Moshage,H., Tanaka,K.E., Engelhardt,D., Rabbani,E., Roy-Chowdhury,N. and Roy-Chowdhury,J. (2000) A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice. Hepatology, 31, 173-181.
17. Oganesian,A., Poot,M., Daum,G., Coats,S.A., Wright,M.B., Seifert,R.A. and Bowen-Pope,D.F. (2003) Protein tyrosine phosphatase RQ is a phosphatidylinositol phosphatase that can regulate cell survival and proliferation. Proc. Natl Acad. Sci. USA, 13, 7563-7568.
18. Wu,H., Goel,V. and Haluska,F.G. (2003) PTEN signaling pathways in melanoma. Oncogene, 22, 3113-3122.
19. Chien,M.W., Chien,C.S., Hsiao,L.D., Lin,C.H. and Yang,C.M. (2003) OxLDL induces mitogen-activated protein kinase activation mediated via PI3-kinase/Akt in vascular smooth muscle cells. J. Lipid Res., 44, 1667-1675.
20. Bruix,J., Sherman,M., Llovet,J.M., Beaugrand,M., Lencioni,R., Burroughs,A.K., Christensen,E., Pagliaro,L., Colombo,M., Rodes,J.; EASL Panel of Experts on HCC (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol., 35, 421-430.
21. Johnson,P.J., Williams,R., Thomas,H., Sherlock,S. and Murray-Lyon,J.M. (1978) Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet, 1, 1006-1009.
22. Lai,C.L., Wu,P.C., Chan,G.C., Lok,A.S. and Lin,H.J. (1988) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer, 62, 479-483.
23. Nerenstone,S.R., Ihde,D.C. and Friedman,M.A. (1988) Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat. Rev., 15, 1-31.
24. Leung,T.W. and Johnson,P.J. (2001) Systemic therapy for hepatocellular carcinoma. Semin. Oncol., 28, 514-520.
25. Bush,J.A. and Li,G. (2002) Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int. J. Cancer 98, 323-330.
26. Matsuda,S., Minowa,A., Suzuki,S. and Koyasu,S. (1999) Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway. J. Immunol., 162, 3321-3326.
27. Meacci,E., Cencetti,F., Donati,C., Nuti,F., Becciolini,L. and Bruni,P. (2004) Sphingosine kinase activity is required for sphingosine-mediated phospholipase D activation in C2C12 myoblasts. Biochem. J., 381, 655-663.
28. Dijkers,P.F., Medema,R.H., Pals,C. et al. (2000) Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27 (KIP1). Mol. Cell. Biol., 20 9138-9148.
29. Delmas,C., Manenti,S., Boudjelal,A., Peyssonnaux,C., Eychene,A. and Darbon,J.M. (2001) The p42/p44 mitogen-activated protein kinase activation triggers p27Kip1 degradation independently of CDK2/cyclin E in NIH 3T3 cells. J. Biol. Chem., 276, 34958-34965.
30. Sulis,M.L. and Parsons,R. (2003) PTEN: from pathology to biology. Trends Cell Biol., 13, 478-483.
31. Toyoshima,H. and Hunter,T. (1994) p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78, 67-74.
32. Johnson,P.J. (2002) Hepatocellular carcinoma: is current therapy really altering outcome? Gut, 51, 459-462.
33. Ng,I.O., Chung,L.P., Tsang,S.W., Lam,C.L., Lai,E.C., Fan,S.T. and Ng,M. (1994) p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene, 9, 985-990.